ADC Bioanalysis Knowledge Base

EMA_ADC_ReflectionPaper

5 min read

EMA Reflection Paper on Antibody-Drug Conjugates (Draft 2020 / Final pending)

概述 Overview

Document: Reflection Paper on Antibody-Drug Conjugates
Agency: EMA (CHMP)
Reference: EMA/CHMP/854503/2022 (or earlier draft reference)
Draft published: 2020 (public consultation)
Final status: As of 2025, the final version is pending; check EMA website for current status
Source: https://www.ema.europa.eu (search “reflection paper antibody drug conjugates”)

Note: This is a reflection paper, not a binding guideline. It represents EMA’s current thinking and may be cited in regulatory submissions as the European regulatory perspective on ADC development. The final version may introduce binding requirements — track publication actively.

The EMA ADC Reflection Paper is the EU equivalent of the FDA ADC ClinPharm Guidance (2024), covering quality/CMC, nonclinical, and clinical aspects specific to ADC development. It is the primary EMA document for ADC-specific regulatory strategy.

核心要点 Key Points

1. CMC / Quality Considerations

The reflection paper dedicates significant attention to ADC manufacturing and characterization — unique among regulatory guidance documents in addressing DAR and linker quality:

DAR characterization requirements:

  • Average DAR by UV/Vis (absorbance at 280 nm and payload λmax), HIC-HPLC, and/or intact mass spectrometry
  • DAR distribution (species-level characterization): HIC-HPLC, CE-SDS, SEC-MS for site-specific; LC-MS/MS for residue-specific DAR (for stochastic conjugation)
  • Release specifications: acceptable DAR range (typically ±0.5 from target average DAR); tightened in later product iterations

Linker stability testing:

  • Forced degradation studies: acidic, basic, oxidative, photolytic, and thermal conditions
  • Accelerated real-time stability studies in PBS and plasma at 37°C
  • Comparison of linker cleavage rate in human plasma vs. anticipated intracellular cleavage rate

Aggregation: ADCs with high DAR or hydrophobic payloads tend to aggregate; aggregate characterization by SEC-HPLC and DLS (dynamic light scattering) is required

2. Nonclinical Requirements

EMA alignment with ICH S9 + S6(R1) dual framework:

  • One relevant species (monkey) sufficient if rat/mouse not pharmacologically relevant
  • Surrogate ADC in rodent: considered case-by-case; required if rodent is needed to characterize payload class toxicity not fully addressed by monkey data
  • Embryo-fetal developmental (EFD) toxicity: not required before FIH; must be completed before NDA/MAA for any non-advanced-cancer setting
  • TCR (tissue cross-reactivity) with clinical mAb: required 37-tissue human panel
  • ADC-specific toxicology endpoints: monitor ocular toxicity (for tubulin inhibitor payloads), neuropathy (MMAE), and organ weights consistent with expected payload effects

EMA expectation unique to EU submissions: May request a rat surrogate ADC study more frequently than FDA, particularly if:

  • The monkey study shows target-mediated on-target toxicity masking payload-driven off-target toxicity
  • A second species is needed for reproductive toxicology assessment

3. Clinical Considerations

Analyte selection (EMA position in reflection paper):

  • Aligns with FDA ADC ClinPharm 2024: minimum TAb + cAb + free payload
  • Additionally recommends considering conjugated payload (hybrid LBA-MS) as an alternative to ELISA-based cAb when anti-drug antibody reagents are unavailable
  • Soluble antigen: recommended as an exploratory PD biomarker in Phase 1

PK characterization:

  • Deconjugation rate (kdc from TAb/cAb divergence): EMA expects this parameter to be reported and interpreted in relation to linker stability in vitro
  • popPK: same expectations as FDA (weight as primary covariate; hepatic/renal function; ADA)

Dose selection:

  • Uses EMA MABEL framework for FIH (EMEA/CHMP/SWP/28367/07 Rev.1)
  • Weight-based vs. flat dosing: same considerations as FDA
  • EMA may require E-R analysis from Phase 1/2 before approving a Phase 3 dose (particularly for accelerated assessment or conditional marketing authorization)

Immunogenicity (ADA):

  • Cross-references EMA immunogenicity guidance for biological medicines
  • ADC-specific: anti-linker and anti-payload ADA must be assessed in at least a subset of ADA-positive patients
  • Drug tolerance assessment: EMA expects acid dissociation step for all ADC ADA programs

4. Key Differences from FDA ADC ClinPharm 2024

TopicEMA Reflection PaperFDA ADC ClinPharm 2024
CMC coverageExtensive (DAR, linker stability, aggregation)Minimal CMC reference
Nonclinical coverageDetailed (surrogate ADC, EFD timing)Brief cross-reference to S9/S6R1
Clinical PKConsistent (TAb + cAb + free payload)Identical position
ADA testingSame tier algorithm; acid dissociation standardSame; acid dissociation recommended
Conditional approvalEMA path allows approval on Phase 2 data with Phase 3 as post-conditionFDA uses accelerated approval similarly but separate legal framework
FIH doseMABEL-based (binding guideline)NOAEL/10 primarily; MABEL encouraged

常见问题和挑战，具体案例和解决方案

Challenge 1: Reflection Paper Is Not Final — Can It Be Cited in a CTA Submission?

EMA position: Reflection papers (even in draft) represent EMA’s current thinking and may be cited as the regulatory context. Applicants should address the reflection paper’s questions proactively in their submission, even if the final guideline has not yet been published.

Solution: In the clinical pharmacology section of a CTA or MAA, include a statement that the program has been designed in accordance with the principles of the EMA ADC Reflection Paper (cite draft reference). Address each major topic (analytes, linker stability, nonclinical strategy) with data or justification. If any reflection paper recommendation is not followed, provide a scientific rationale.

Challenge 2: EMA Requests Rat Surrogate ADC Study — Not Required by FDA

Problem: FDA accepted a cynomolgus monkey-only GLP tox study for a Nectin-4 ADC (not expressed in rat). EMA now requests a rat surrogate ADC study to characterize MMAE payload toxicity in a second species.

Solution:

  1. Assess feasibility of a rat surrogate: requires generating a rat-specific anti-Nectin-4 antibody, conjugating to MMAE via Val-Cit linker, characterizing DAR and activity → significant resource investment
  2. Alternative approach: provide a comprehensive MMAE class toxicology summary from all approved MMAE ADC programs (brentuximab, polatuzumab, enfortumab) — demonstrate MMAE payload toxicity is well-characterized across species
  3. Request scientific advice from EMA to resolve the question before committing to the surrogate ADC study

Precedent: The EMA has accepted class-based payload toxicology arguments for MMAE-based ADCs given the extensive published safety data. Novel payloads (PBDs, alpha-amanitin) are more likely to require a second-species study.

Graph View

Backlinks